Market Access Capping the cost of insulin: altruistic or strategic? The price of insulin has become one of the most talked about issues across the pharma industry.
News Lilly shares disappointing A4 study results for solanezumab The drug only targets soluble amyloid beta-protein and doesn't clear amyloid plaques.
News Lilly slashes insulin price 70%, patient cost cap now $35 Lilly trying to make it easier for patients to access its insulin and help Americans generally.
R&D Almirall/Lilly lebrikizumab offers potential long-term manag... Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable
News Lilly invests another $3bn in its manufacturing network Lilly will spend $3 billion on a recently acquired Wisconsin plant for injectable medicines, including diabetes and obesity drugs.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
